Dr. Peter Martin

Nearly 90 percent of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.

There is considerable variation in the management of mantle cell lymphoma across different clinical settings, and some strategies do not always conform with what might be expected, according to an analysis by investigators from Weill Cornell Medicine and other leading health institutions.

Weill Cornell Medicine has been awarded a five-year, $9 million Program Project Grant (P01) from the National Cancer Institute (NCI) to better understand how and why patients with an aggressive and incurable form of lymphoma initially respond to treatment, only to relapse over time. 

Newer, non-chemotherapy drugs benefit many patients with mantle cell lymphoma, an incurable form of blood cancer, and deserve deeper study in clinical trials, according to an editorial published Sept. 12 in Blood by scientists at Weill Cornell Medicine and NewYork-Presbyterian.

For decades, Weill Cornell has been a leader in the research revolution that's making lymphoma a survivable disease.